APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anti-Parkinson's Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Anti-Parkinson's Disease Drugs Market Analysis and Forecast 2026-2032

27 December 2025215 pages

Choose your research edition.

Industry ResearchAnti-Parkinson's Disease Drugs Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Parkinson's Disease Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Anti-Parkinson's Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Parkinson's Disease Drugs Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Parkinson's Disease Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Anti-Parkinson's Disease Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Anti-Parkinson's Disease Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Anti-Parkinson's Disease Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Anti-Parkinson's Disease Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Anti-Parkinson's Disease Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Anti-Parkinson's Disease Drugs include Zhejiang Huahai Pharmaceutical Co., Ltd., Tianjin Lisheng Pharmaceutical Co., Ltd., Ningbo Dahongying Pharmaceutical Co., Ltd., Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Hunan Zhongnan Pharmaceutical Co., Ltd., Hangzhou Guoguang Pharmaceutical Co., Ltd., Guangzhou Kanghe Pharmaceutical Co., Ltd., Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. and Changzhou Kangpu Pharmaceutical Co., Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Anti-Parkinson's Disease Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti-Parkinson's Disease Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Anti-Parkinson's Disease Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-Parkinson's Disease Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-Parkinson's Disease Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Anti-Parkinson's Disease Drugs sales, projected growth trends, production technology, application and end-user industry.

Anti-Parkinson's Disease Drugs Segment by Company

Zhejiang Huahai Pharmaceutical Co., Ltd.

Tianjin Lisheng Pharmaceutical Co., Ltd.

Ningbo Dahongying Pharmaceutical Co., Ltd.

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Hunan Zhongnan Pharmaceutical Co., Ltd.

Hangzhou Guoguang Pharmaceutical Co., Ltd.

Guangzhou Kanghe Pharmaceutical Co., Ltd.

Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.

Changzhou Kangpu Pharmaceutical Co., Ltd.

Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.

Beijing Fuyuan Pharmaceutical Co., Ltd.

Valeant

Teva Pharmaceutical

Stada Arzneimittel

Roche Holding AG

Orion

Novartis

Merck

Lundbeck

Kyowa Kirin

GSK

Endo International plc

Desitin Arzneimittel

Boehringer Ingelheim

Bausch Health

Astellas Pharma

Apokyn

Akorn

Abbvie

Anti-Parkinson's Disease Drugs Segment by Type

Anticholinergics

Dopaminergics

Anti-Parkinson's Disease Drugs Segment by Application

Pharmacy

Hospital

Clinic

Other

Anti-Parkinson's Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Parkinson's Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Parkinson's Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Parkinson's Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Anti-Parkinson's Disease Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Anti-Parkinson's Disease Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Parkinson's Disease Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti-Parkinson's Disease Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Anticholinergics Major Manufacturers Table 3. Dopaminergics Major Manufacturers Table 4. Global Anti-Parkinson's Disease Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Pharmacy Major Manufacturers Table 6. Hospital Major Manufacturers Table 7. Clinic Major Manufacturers Table 8. Other Major Manufacturers Table 9. Anti-Parkinson's Disease Drugs Industry Trends Table 10. Anti-Parkinson's Disease Drugs Industry Drivers Table 11. Anti-Parkinson's Disease Drugs Industry Opportunities and Challenges Table 12. Anti-Parkinson's Disease Drugs Industry Restraints Table 13. Global Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Anti-Parkinson's Disease Drugs Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Anti-Parkinson's Disease Drugs Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region (2021-2026) Table 17. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region (2027-2032) Table 18. Global Anti-Parkinson's Disease Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Anti-Parkinson's Disease Drugs Sales by Region (2021-2026) & (K Units) Table 20. Global Anti-Parkinson's Disease Drugs Sales by Region (2027-2032) & (K Units) Table 21. Global Anti-Parkinson's Disease Drugs Sales Market Share by Region (2021-2026) Table 22. Global Anti-Parkinson's Disease Drugs Sales Market Share by Region (2027-2032) Table 23. Global Anti-Parkinson's Disease Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Anti-Parkinson's Disease Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Anti-Parkinson's Disease Drugs Sales Market Share by Manufacturers (2021-2026) Table 27. Global Anti-Parkinson's Disease Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Anti-Parkinson's Disease Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Anti-Parkinson's Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Anti-Parkinson's Disease Drugs Manufacturers, Product Type & Application Table 31. Global Anti-Parkinson's Disease Drugs Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Anti-Parkinson's Disease Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Anti-Parkinson's Disease Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Anti-Parkinson's Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Anti-Parkinson's Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2021-2026) Table 38. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2027-2032) Table 39. Global Anti-Parkinson's Disease Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 41. Global Anti-Parkinson's Disease Drugs Sales by Type (2027-2032) & (K Units) Table 42. Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2026) Table 43. Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2027-2032) Table 44. Global Anti-Parkinson's Disease Drugs Price by Type (2021-2026) & (US$/Unit) Table 45. Global Anti-Parkinson's Disease Drugs Price by Type (2027-2032) & (US$/Unit) Table 46. Global Anti-Parkinson's Disease Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Anti-Parkinson's Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Anti-Parkinson's Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2021-2026) Table 50. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2027-2032) Table 51. Global Anti-Parkinson's Disease Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 53. Global Anti-Parkinson's Disease Drugs Sales by Application (2027-2032) & (K Units) Table 54. Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2021-2026) Table 55. Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2027-2032) Table 56. Global Anti-Parkinson's Disease Drugs Price by Application (2021-2026) & (US$/Unit) Table 57. Global Anti-Parkinson's Disease Drugs Price by Application (2027-2032) & (US$/Unit) Table 58. Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information Table 59. Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview Table 60. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 62. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Development Table 63. Tianjin Lisheng Pharmaceutical Co., Ltd. Company Information Table 64. Tianjin Lisheng Pharmaceutical Co., Ltd. Business Overview Table 65. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 67. Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Development Table 68. Ningbo Dahongying Pharmaceutical Co., Ltd. Company Information Table 69. Ningbo Dahongying Pharmaceutical Co., Ltd. Business Overview Table 70. Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 72. Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Development Table 73. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information Table 74. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview Table 75. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 77. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Development Table 78. Hunan Zhongnan Pharmaceutical Co., Ltd. Company Information Table 79. Hunan Zhongnan Pharmaceutical Co., Ltd. Business Overview Table 80. Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 82. Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Development Table 83. Hangzhou Guoguang Pharmaceutical Co., Ltd. Company Information Table 84. Hangzhou Guoguang Pharmaceutical Co., Ltd. Business Overview Table 85. Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 87. Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Development Table 88. Guangzhou Kanghe Pharmaceutical Co., Ltd. Company Information Table 89. Guangzhou Kanghe Pharmaceutical Co., Ltd. Business Overview Table 90. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 92. Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Development Table 93. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Company Information Table 94. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Business Overview Table 95. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 97. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Development Table 98. Changzhou Kangpu Pharmaceutical Co., Ltd. Company Information Table 99. Changzhou Kangpu Pharmaceutical Co., Ltd. Business Overview Table 100. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 102. Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Development Table 103. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Company Information Table 104. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Business Overview Table 105. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 107. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Development Table 108. Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information Table 109. Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview Table 110. Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 112. Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Development Table 113. Valeant Company Information Table 114. Valeant Business Overview Table 115. Valeant Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Valeant Anti-Parkinson's Disease Drugs Product Portfolio Table 117. Valeant Recent Development Table 118. Teva Pharmaceutical Company Information Table 119. Teva Pharmaceutical Business Overview Table 120. Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Portfolio Table 122. Teva Pharmaceutical Recent Development Table 123. Stada Arzneimittel Company Information Table 124. Stada Arzneimittel Business Overview Table 125. Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio Table 127. Stada Arzneimittel Recent Development Table 128. Roche Holding AG Company Information Table 129. Roche Holding AG Business Overview Table 130. Roche Holding AG Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Roche Holding AG Anti-Parkinson's Disease Drugs Product Portfolio Table 132. Roche Holding AG Recent Development Table 133. Orion Company Information Table 134. Orion Business Overview Table 135. Orion Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Orion Anti-Parkinson's Disease Drugs Product Portfolio Table 137. Orion Recent Development Table 138. Novartis Company Information Table 139. Novartis Business Overview Table 140. Novartis Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Novartis Anti-Parkinson's Disease Drugs Product Portfolio Table 142. Novartis Recent Development Table 143. Merck Company Information Table 144. Merck Business Overview Table 145. Merck Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Merck Anti-Parkinson's Disease Drugs Product Portfolio Table 147. Merck Recent Development Table 148. Lundbeck Company Information Table 149. Lundbeck Business Overview Table 150. Lundbeck Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Lundbeck Anti-Parkinson's Disease Drugs Product Portfolio Table 152. Lundbeck Recent Development Table 153. Kyowa Kirin Company Information Table 154. Kyowa Kirin Business Overview Table 155. Kyowa Kirin Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Kyowa Kirin Anti-Parkinson's Disease Drugs Product Portfolio Table 157. Kyowa Kirin Recent Development Table 158. GSK Company Information Table 159. GSK Business Overview Table 160. GSK Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. GSK Anti-Parkinson's Disease Drugs Product Portfolio Table 162. GSK Recent Development Table 163. Endo International plc Company Information Table 164. Endo International plc Business Overview Table 165. Endo International plc Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Endo International plc Anti-Parkinson's Disease Drugs Product Portfolio Table 167. Endo International plc Recent Development Table 168. Desitin Arzneimittel Company Information Table 169. Desitin Arzneimittel Business Overview Table 170. Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 171. Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio Table 172. Desitin Arzneimittel Recent Development Table 173. Boehringer Ingelheim Company Information Table 174. Boehringer Ingelheim Business Overview Table 175. Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 176. Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Portfolio Table 177. Boehringer Ingelheim Recent Development Table 178. Bausch Health Company Information Table 179. Bausch Health Business Overview Table 180. Bausch Health Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 181. Bausch Health Anti-Parkinson's Disease Drugs Product Portfolio Table 182. Bausch Health Recent Development Table 183. Astellas Pharma Company Information Table 184. Astellas Pharma Business Overview Table 185. Astellas Pharma Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 186. Astellas Pharma Anti-Parkinson's Disease Drugs Product Portfolio Table 187. Astellas Pharma Recent Development Table 188. Apokyn Company Information Table 189. Apokyn Business Overview Table 190. Apokyn Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 191. Apokyn Anti-Parkinson's Disease Drugs Product Portfolio Table 192. Apokyn Recent Development Table 193. Akorn Company Information Table 194. Akorn Business Overview Table 195. Akorn Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 196. Akorn Anti-Parkinson's Disease Drugs Product Portfolio Table 197. Akorn Recent Development Table 198. Abbvie Company Information Table 199. Abbvie Business Overview Table 200. Abbvie Anti-Parkinson's Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 201. Abbvie Anti-Parkinson's Disease Drugs Product Portfolio Table 202. Abbvie Recent Development Table 203. North America Anti-Parkinson's Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 204. North America Anti-Parkinson's Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 205. North America Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 206. North America Anti-Parkinson's Disease Drugs Sales by Type (2027-2032) & (K Units) Table 207. North America Anti-Parkinson's Disease Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 208. North America Anti-Parkinson's Disease Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 209. North America Anti-Parkinson's Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 210. North America Anti-Parkinson's Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 211. North America Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 212. North America Anti-Parkinson's Disease Drugs Sales by Application (2027-2032) & (K Units) Table 213. North America Anti-Parkinson's Disease Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 214. North America Anti-Parkinson's Disease Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 215. North America Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 216. North America Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 217. North America Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 218. North America Anti-Parkinson's Disease Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 219. North America Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 220. North America Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units) Table 221. North America Anti-Parkinson's Disease Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 222. North America Anti-Parkinson's Disease Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 223. United States Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 224. Canada Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 225. Mexico Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 226. Europe Anti-Parkinson's Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 227. Europe Anti-Parkinson's Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 228. Europe Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 229. Europe Anti-Parkinson's Disease Drugs Sales by Type (2027-2032) & (K Units) Table 230. Europe Anti-Parkinson's Disease Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 231. Europe Anti-Parkinson's Disease Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 232. Europe Anti-Parkinson's Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 233. Europe Anti-Parkinson's Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 234. Europe Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 235. Europe Anti-Parkinson's Disease Drugs Sales by Application (2027-2032) & (K Units) Table 236. Europe Anti-Parkinson's Disease Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 237. Europe Anti-Parkinson's Disease Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 238. Europe Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 239. Europe Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 240. Europe Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 241. Europe Anti-Parkinson's Disease Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 242. Europe Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 243. Europe Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units) Table 244. Europe Anti-Parkinson's Disease Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 245. Europe Anti-Parkinson's Disease Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 246. Germany Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 247. France Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 248. U.K. Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 249. Italy Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 250. Russia Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 251. Spain Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 252. Netherlands Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 253. Switzerland Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 254. Sweden Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 255. Poland Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 256. China Anti-Parkinson's Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 257. China Anti-Parkinson's Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 258. China Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 259. China Anti-Parkinson's Disease Drugs Sales by Type (2027-2032) & (K Units) Table 260. China Anti-Parkinson's Disease Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 261. China Anti-Parkinson's Disease Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 262. China Anti-Parkinson's Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 263. China Anti-Parkinson's Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 264. China Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 265. China Anti-Parkinson's Disease Drugs Sales by Application (2027-2032) & (K Units) Table 266. China Anti-Parkinson's Disease Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 267. China Anti-Parkinson's Disease Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 268. Asia Anti-Parkinson's Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 269. Asia Anti-Parkinson's Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 270. Asia Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 271. Asia Anti-Parkinson's Disease Drugs Sales by Type (2027-2032) & (K Units) Table 272. Asia Anti-Parkinson's Disease Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 273. Asia Anti-Parkinson's Disease Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 274. Asia Anti-Parkinson's Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 275. Asia Anti-Parkinson's Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 276. Asia Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 277. Asia Anti-Parkinson's Disease Drugs Sales by Application (2027-2032) & (K Units) Table 278. Asia Anti-Parkinson's Disease Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 279. Asia Anti-Parkinson's Disease Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 280. Asia Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 281. Asia Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 282. Asia Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 283. Asia Anti-Parkinson's Disease Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 284. Asia Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 285. Asia Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units) Table 286. Asia Anti-Parkinson's Disease Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 287. Asia Anti-Parkinson's Disease Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 288. Japan Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 289. South Korea Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 290. India Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 291. Australia Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 292. Taiwan Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 293. Southeast Asia Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 294. SAMEA Anti-Parkinson's Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 295. SAMEA Anti-Parkinson's Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 296. SAMEA Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 297. SAMEA Anti-Parkinson's Disease Drugs Sales by Type (2027-2032) & (K Units) Table 298. SAMEA Anti-Parkinson's Disease Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 299. SAMEA Anti-Parkinson's Disease Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 300. SAMEA Anti-Parkinson's Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 301. SAMEA Anti-Parkinson's Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 302. SAMEA Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 303. SAMEA Anti-Parkinson's Disease Drugs Sales by Application (2027-2032) & (K Units) Table 304. SAMEA Anti-Parkinson's Disease Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 305. SAMEA Anti-Parkinson's Disease Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 306. SAMEA Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 307. SAMEA Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 308. SAMEA Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 309. SAMEA Anti-Parkinson's Disease Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 310. SAMEA Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 311. SAMEA Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units) Table 312. SAMEA Anti-Parkinson's Disease Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 313. SAMEA Anti-Parkinson's Disease Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 314. Brazil Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 315. Argentina Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 316. Chile Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 317. Colombia Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 318. Peru Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 319. Saudi Arabia Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 320. Israel Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 321. UAE Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 322. Turkey Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 323. Iran Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 324. Egypt Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Table 325. Key Raw Materials Table 326. Raw Materials Key Suppliers Table 327. Anti-Parkinson's Disease Drugs Distributors List Table 328. Anti-Parkinson's Disease Drugs Customers List Table 329. Research Programs/Design for This Report Table 330. Authors List of This Report Table 331. Secondary Sources Table 332. Primary Sources List of Figures Figure 1. Anti-Parkinson's Disease Drugs Image Figure 2. Global Anti-Parkinson's Disease Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Parkinson's Disease Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Anticholinergics Image Figure 5. Dopaminergics Image Figure 6. Global Anti-Parkinson's Disease Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Anti-Parkinson's Disease Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Pharmacy Image Figure 9. Hospital Image Figure 10. Clinic Image Figure 11. Other Image Figure 12. Global Anti-Parkinson's Disease Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 14. Global Anti-Parkinson's Disease Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region (2021-2032) Figure 17. Global Anti-Parkinson's Disease Drugs Sales (2021-2032) & (K Units) Figure 18. Global Anti-Parkinson's Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Anti-Parkinson's Disease Drugs Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Anti-Parkinson's Disease Drugs Sales YoY (2021-2032) & (K Units) Figure 21. Europe Anti-Parkinson's Disease Drugs Sales YoY (2021-2032) & (K Units) Figure 22. China Anti-Parkinson's Disease Drugs Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Anti-Parkinson's Disease Drugs Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Anti-Parkinson's Disease Drugs Sales YoY (2021-2032) & (K Units) Figure 25. Global Anti-Parkinson's Disease Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Anti-Parkinson's Disease Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Anti-Parkinson's Disease Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2021-2032) Figure 31. Global Anti-Parkinson's Disease Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Anti-Parkinso

Scope & coverage.

Types
  • Anticholinergics
  • Dopaminergics
Applications
  • Pharmacy
  • Hospital
  • Clinic
  • Other
Companies covered
  • Zhejiang Huahai Pharmaceutical Co., Ltd.
  • Tianjin Lisheng Pharmaceutical Co., Ltd.
  • Ningbo Dahongying Pharmaceutical Co., Ltd.
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  • Hunan Zhongnan Pharmaceutical Co., Ltd.
  • Hangzhou Guoguang Pharmaceutical Co., Ltd.
  • Guangzhou Kanghe Pharmaceutical Co., Ltd.
  • Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
  • Changzhou Kangpu Pharmaceutical Co., Ltd.
  • Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
  • Beijing Fuyuan Pharmaceutical Co., Ltd.
  • Valeant
  • Teva Pharmaceutical
  • Stada Arzneimittel
  • Roche Holding AG
  • Orion
  • Novartis
  • Merck
  • Lundbeck
  • Kyowa Kirin
  • GSK
  • Endo International plc
  • Desitin Arzneimittel
  • Boehringer Ingelheim
  • Bausch Health
  • Astellas Pharma
  • Apokyn
  • Akorn
  • Abbvie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti-Parkinson's Disease Drugs Market by Type
  3. 1.2.1 Global Anti-Parkinson's Disease Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Anticholinergics
  5. 1.2.3 Dopaminergics
  6. 1.3 Anti-Parkinson's Disease Drugs Market by Application
  7. 1.3.1 Global Anti-Parkinson's Disease Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Pharmacy
  9. 1.3.3 Hospital
  10. 1.3.4 Clinic
  11. 1.3.5 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Anti-Parkinson's Disease Drugs Market Dynamics
  1. 2.1 Anti-Parkinson's Disease Drugs Industry Trends
  2. 2.2 Anti-Parkinson's Disease Drugs Industry Drivers
  3. 2.3 Anti-Parkinson's Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Anti-Parkinson's Disease Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Anti-Parkinson's Disease Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Anti-Parkinson's Disease Drugs Revenue by Region
  3. 3.2.1 Global Anti-Parkinson's Disease Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti-Parkinson's Disease Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Anti-Parkinson's Disease Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Anti-Parkinson's Disease Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Anti-Parkinson's Disease Drugs Sales by Region
  9. 3.4.1 Global Anti-Parkinson's Disease Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Anti-Parkinson's Disease Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Anti-Parkinson's Disease Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Anti-Parkinson's Disease Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Anti-Parkinson's Disease Drugs Revenue by Manufacturers
  2. 4.1.1 Global Anti-Parkinson's Disease Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Anti-Parkinson's Disease Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Anti-Parkinson's Disease Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti-Parkinson's Disease Drugs Sales by Manufacturers
  6. 4.2.1 Global Anti-Parkinson's Disease Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Anti-Parkinson's Disease Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Anti-Parkinson's Disease Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Anti-Parkinson's Disease Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Anti-Parkinson's Disease Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Anti-Parkinson's Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Anti-Parkinson's Disease Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Anti-Parkinson's Disease Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Anti-Parkinson's Disease Drugs Market CR5 and HHI
  16. 4.8.2 2025 Anti-Parkinson's Disease Drugs Tier 1, Tier 2, and Tier 3
5 Anti-Parkinson's Disease Drugs Market by Type
  1. 5.1 Global Anti-Parkinson's Disease Drugs Revenue by Type
  2. 5.1.1 Global Anti-Parkinson's Disease Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Anti-Parkinson's Disease Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Anti-Parkinson's Disease Drugs Sales by Type
  6. 5.2.1 Global Anti-Parkinson's Disease Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-Parkinson's Disease Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Anti-Parkinson's Disease Drugs Price by Type
6 Anti-Parkinson's Disease Drugs Market by Application
  1. 6.1 Global Anti-Parkinson's Disease Drugs Revenue by Application
  2. 6.1.1 Global Anti-Parkinson's Disease Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Anti-Parkinson's Disease Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Anti-Parkinson's Disease Drugs Sales by Application
  6. 6.2.1 Global Anti-Parkinson's Disease Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Anti-Parkinson's Disease Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Anti-Parkinson's Disease Drugs Price by Application
7 Company Profiles
  1. 7.1 Zhejiang Huahai Pharmaceutical Co., Ltd.
  2. 7.1.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
  3. 7.1.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
  4. 7.1.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  6. 7.1.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
  7. 7.2 Tianjin Lisheng Pharmaceutical Co., Ltd.
  8. 7.2.1 Tianjin Lisheng Pharmaceutical Co., Ltd. Company Information
  9. 7.2.2 Tianjin Lisheng Pharmaceutical Co., Ltd. Business Overview
  10. 7.2.3 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  12. 7.2.5 Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Developments
  13. 7.3 Ningbo Dahongying Pharmaceutical Co., Ltd.
  14. 7.3.1 Ningbo Dahongying Pharmaceutical Co., Ltd. Company Information
  15. 7.3.2 Ningbo Dahongying Pharmaceutical Co., Ltd. Business Overview
  16. 7.3.3 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  18. 7.3.5 Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Developments
  19. 7.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  20. 7.4.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information
  21. 7.4.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview
  22. 7.4.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  24. 7.4.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
  25. 7.5 Hunan Zhongnan Pharmaceutical Co., Ltd.
  26. 7.5.1 Hunan Zhongnan Pharmaceutical Co., Ltd. Company Information
  27. 7.5.2 Hunan Zhongnan Pharmaceutical Co., Ltd. Business Overview
  28. 7.5.3 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  30. 7.5.5 Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Developments
  31. 7.6 Hangzhou Guoguang Pharmaceutical Co., Ltd.
  32. 7.6.1 Hangzhou Guoguang Pharmaceutical Co., Ltd. Company Information
  33. 7.6.2 Hangzhou Guoguang Pharmaceutical Co., Ltd. Business Overview
  34. 7.6.3 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  36. 7.6.5 Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Developments
  37. 7.7 Guangzhou Kanghe Pharmaceutical Co., Ltd.
  38. 7.7.1 Guangzhou Kanghe Pharmaceutical Co., Ltd. Company Information
  39. 7.7.2 Guangzhou Kanghe Pharmaceutical Co., Ltd. Business Overview
  40. 7.7.3 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  42. 7.7.5 Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Developments
  43. 7.8 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
  44. 7.8.1 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Company Information
  45. 7.8.2 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Business Overview
  46. 7.8.3 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  48. 7.8.5 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Developments
  49. 7.9 Changzhou Kangpu Pharmaceutical Co., Ltd.
  50. 7.9.1 Changzhou Kangpu Pharmaceutical Co., Ltd. Company Information
  51. 7.9.2 Changzhou Kangpu Pharmaceutical Co., Ltd. Business Overview
  52. 7.9.3 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  54. 7.9.5 Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Developments
  55. 7.10 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
  56. 7.10.1 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Company Information
  57. 7.10.2 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Business Overview
  58. 7.10.3 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  60. 7.10.5 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Developments
  61. 7.11 Beijing Fuyuan Pharmaceutical Co., Ltd.
  62. 7.11.1 Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information
  63. 7.11.2 Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview
  64. 7.11.3 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  66. 7.11.5 Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Developments
  67. 7.12 Valeant
  68. 7.12.1 Valeant Company Information
  69. 7.12.2 Valeant Business Overview
  70. 7.12.3 Valeant Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Valeant Anti-Parkinson's Disease Drugs Product Portfolio
  72. 7.12.5 Valeant Recent Developments
  73. 7.13 Teva Pharmaceutical
  74. 7.13.1 Teva Pharmaceutical Company Information
  75. 7.13.2 Teva Pharmaceutical Business Overview
  76. 7.13.3 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Portfolio
  78. 7.13.5 Teva Pharmaceutical Recent Developments
  79. 7.14 Stada Arzneimittel
  80. 7.14.1 Stada Arzneimittel Company Information
  81. 7.14.2 Stada Arzneimittel Business Overview
  82. 7.14.3 Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio
  84. 7.14.5 Stada Arzneimittel Recent Developments
  85. 7.15 Roche Holding AG
  86. 7.15.1 Roche Holding AG Company Information
  87. 7.15.2 Roche Holding AG Business Overview
  88. 7.15.3 Roche Holding AG Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Roche Holding AG Anti-Parkinson's Disease Drugs Product Portfolio
  90. 7.15.5 Roche Holding AG Recent Developments
  91. 7.16 Orion
  92. 7.16.1 Orion Company Information
  93. 7.16.2 Orion Business Overview
  94. 7.16.3 Orion Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Orion Anti-Parkinson's Disease Drugs Product Portfolio
  96. 7.16.5 Orion Recent Developments
  97. 7.17 Novartis
  98. 7.17.1 Novartis Company Information
  99. 7.17.2 Novartis Business Overview
  100. 7.17.3 Novartis Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Novartis Anti-Parkinson's Disease Drugs Product Portfolio
  102. 7.17.5 Novartis Recent Developments
  103. 7.18 Merck
  104. 7.18.1 Merck Company Information
  105. 7.18.2 Merck Business Overview
  106. 7.18.3 Merck Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Merck Anti-Parkinson's Disease Drugs Product Portfolio
  108. 7.18.5 Merck Recent Developments
  109. 7.19 Lundbeck
  110. 7.19.1 Lundbeck Company Information
  111. 7.19.2 Lundbeck Business Overview
  112. 7.19.3 Lundbeck Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Lundbeck Anti-Parkinson's Disease Drugs Product Portfolio
  114. 7.19.5 Lundbeck Recent Developments
  115. 7.20 Kyowa Kirin
  116. 7.20.1 Kyowa Kirin Company Information
  117. 7.20.2 Kyowa Kirin Business Overview
  118. 7.20.3 Kyowa Kirin Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Kyowa Kirin Anti-Parkinson's Disease Drugs Product Portfolio
  120. 7.20.5 Kyowa Kirin Recent Developments
  121. 7.21 GSK
  122. 7.21.1 GSK Company Information
  123. 7.21.2 GSK Business Overview
  124. 7.21.3 GSK Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 GSK Anti-Parkinson's Disease Drugs Product Portfolio
  126. 7.21.5 GSK Recent Developments
  127. 7.22 Endo International plc
  128. 7.22.1 Endo International plc Company Information
  129. 7.22.2 Endo International plc Business Overview
  130. 7.22.3 Endo International plc Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Endo International plc Anti-Parkinson's Disease Drugs Product Portfolio
  132. 7.22.5 Endo International plc Recent Developments
  133. 7.23 Desitin Arzneimittel
  134. 7.23.1 Desitin Arzneimittel Company Information
  135. 7.23.2 Desitin Arzneimittel Business Overview
  136. 7.23.3 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio
  138. 7.23.5 Desitin Arzneimittel Recent Developments
  139. 7.24 Boehringer Ingelheim
  140. 7.24.1 Boehringer Ingelheim Company Information
  141. 7.24.2 Boehringer Ingelheim Business Overview
  142. 7.24.3 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Portfolio
  144. 7.24.5 Boehringer Ingelheim Recent Developments
  145. 7.25 Bausch Health
  146. 7.25.1 Bausch Health Company Information
  147. 7.25.2 Bausch Health Business Overview
  148. 7.25.3 Bausch Health Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  149. 7.25.4 Bausch Health Anti-Parkinson's Disease Drugs Product Portfolio
  150. 7.25.5 Bausch Health Recent Developments
  151. 7.26 Astellas Pharma
  152. 7.26.1 Astellas Pharma Company Information
  153. 7.26.2 Astellas Pharma Business Overview
  154. 7.26.3 Astellas Pharma Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  155. 7.26.4 Astellas Pharma Anti-Parkinson's Disease Drugs Product Portfolio
  156. 7.26.5 Astellas Pharma Recent Developments
  157. 7.27 Apokyn
  158. 7.27.1 Apokyn Company Information
  159. 7.27.2 Apokyn Business Overview
  160. 7.27.3 Apokyn Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  161. 7.27.4 Apokyn Anti-Parkinson's Disease Drugs Product Portfolio
  162. 7.27.5 Apokyn Recent Developments
  163. 7.28 Akorn
  164. 7.28.1 Akorn Company Information
  165. 7.28.2 Akorn Business Overview
  166. 7.28.3 Akorn Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  167. 7.28.4 Akorn Anti-Parkinson's Disease Drugs Product Portfolio
  168. 7.28.5 Akorn Recent Developments
  169. 7.29 Abbvie
  170. 7.29.1 Abbvie Company Information
  171. 7.29.2 Abbvie Business Overview
  172. 7.29.3 Abbvie Anti-Parkinson's Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  173. 7.29.4 Abbvie Anti-Parkinson's Disease Drugs Product Portfolio
  174. 7.29.5 Abbvie Recent Developments
8 North America
  1. 8.1 North America Anti-Parkinson's Disease Drugs Market Size by Type
  2. 8.1.1 North America Anti-Parkinson's Disease Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Anti-Parkinson's Disease Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Anti-Parkinson's Disease Drugs Price by Type (2021-2032)
  5. 8.2 North America Anti-Parkinson's Disease Drugs Market Size by Application
  6. 8.2.1 North America Anti-Parkinson's Disease Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Anti-Parkinson's Disease Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Anti-Parkinson's Disease Drugs Price by Application (2021-2032)
  9. 8.3 North America Anti-Parkinson's Disease Drugs Market Size by Country
  10. 8.3.1 North America Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Anti-Parkinson's Disease Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Anti-Parkinson's Disease Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Anti-Parkinson's Disease Drugs Market Size by Type
  2. 9.1.1 Europe Anti-Parkinson's Disease Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Anti-Parkinson's Disease Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Anti-Parkinson's Disease Drugs Price by Type (2021-2032)
  5. 9.2 Europe Anti-Parkinson's Disease Drugs Market Size by Application
  6. 9.2.1 Europe Anti-Parkinson's Disease Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Anti-Parkinson's Disease Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Anti-Parkinson's Disease Drugs Price by Application (2021-2032)
  9. 9.3 Europe Anti-Parkinson's Disease Drugs Market Size by Country
  10. 9.3.1 Europe Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Anti-Parkinson's Disease Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Anti-Parkinson's Disease Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Anti-Parkinson's Disease Drugs Market Size by Type
  2. 10.1.1 China Anti-Parkinson's Disease Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Anti-Parkinson's Disease Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Anti-Parkinson's Disease Drugs Price by Type (2021-2032)
  5. 10.2 China Anti-Parkinson's Disease Drugs Market Size by Application
  6. 10.2.1 China Anti-Parkinson's Disease Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Anti-Parkinson's Disease Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Anti-Parkinson's Disease Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti-Parkinson's Disease Drugs Market Size by Type
  2. 11.1.1 Asia Anti-Parkinson's Disease Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Anti-Parkinson's Disease Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Anti-Parkinson's Disease Drugs Price by Type (2021-2032)
  5. 11.2 Asia Anti-Parkinson's Disease Drugs Market Size by Application
  6. 11.2.1 Asia Anti-Parkinson's Disease Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Anti-Parkinson's Disease Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Anti-Parkinson's Disease Drugs Price by Application (2021-2032)
  9. 11.3 Asia Anti-Parkinson's Disease Drugs Market Size by Country
  10. 11.3.1 Asia Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Anti-Parkinson's Disease Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Anti-Parkinson's Disease Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti-Parkinson's Disease Drugs Market Size by Type
  2. 12.1.1 SAMEA Anti-Parkinson's Disease Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Anti-Parkinson's Disease Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Anti-Parkinson's Disease Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Anti-Parkinson's Disease Drugs Market Size by Application
  6. 12.2.1 SAMEA Anti-Parkinson's Disease Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Anti-Parkinson's Disease Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Anti-Parkinson's Disease Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Anti-Parkinson's Disease Drugs Market Size by Country
  10. 12.3.1 SAMEA Anti-Parkinson's Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Anti-Parkinson's Disease Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Anti-Parkinson's Disease Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Anti-Parkinson's Disease Drugs Value Chain Analysis
  2. 13.1.1 Anti-Parkinson's Disease Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Anti-Parkinson's Disease Drugs Production Mode & Process
  6. 13.2 Anti-Parkinson's Disease Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Anti-Parkinson's Disease Drugs Distributors
  9. 13.2.3 Anti-Parkinson's Disease Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst